Marshall Wace’s Medifast MED Stock Holding History

Marshall Wace’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-166,199	Closed	-$2.24M	–	2978
2025 Q1	$2.24M	Buy	166,199 +61,973	+59%	+$931K	﹤0.01%	1425
2024 Q4	$1.84M	Buy	+104,226	New	+$1.93M	﹤0.01%	1474
2023 Q4	–	Sell	-12,500	Closed	-$936K	–	2441
2023 Q3	$936K	Sell	12,500 -16,103	-56%	-$1.43M	﹤0.01%	1520
2023 Q2	$2.64M	Buy	+28,603	New	+$2.55M	0.01%	1276
2022 Q3	–	Sell	-1,832	Closed	-$331K	–	3615
2022 Q2	$331K	Buy	+1,832	New	+$328K	﹤0.01%	2987
2022 Q1	–	Sell	-36,425	Closed	-$7.63M	–	3737
2021 Q4	$7.63M	Buy	+36,425	New	+$7.53M	0.01%	1063
2019 Q4	–	Sell	-74,006	Closed	-$7.67M	–	1927
2019 Q3	$7.67M	Sell	74,006 -494	-0.7%	-$53.1K	0.06%	369
2019 Q2	$9.56M	Buy	74,500 +46,740	+168%	+$6.49M	0.08%	293
2019 Q1	$3.54M	Buy	27,760 +14,659	+112%	+$1.86M	0.03%	569
2018 Q4	$1.64M	Buy	+13,101	New	+$2.24M	0.02%	777
2018 Q2	–	Sell	-6,900	Closed	-$645K	–	780
2018 Q1	$645K	Buy	+6,900	New	+$516K	0.03%	311
2016 Q3	–	Sell	-75,823	Closed	-$2.52M	–	1054
2016 Q2	$2.52M	Buy	+75,823	New	+$2.45M	0.02%	534

Other funds holding MED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Marshall Wace's MED Position: Q2 2025 in Review

Marshall Wace sold out of Medifast (MED) in Q2 2025, closing a stake of 166,199 shares — an estimated $2.24M sold.

Marshall Wace first reported a position in MED in Q2 2016 and held it in 12 quarters. The position peaked at $9.56M in Q2 2019. 120 funds tracked by Wall St. Rank hold MED as of Q2 2025.

Marshall Wace reported no remaining Medifast position as of Q2 2025 after selling out during the quarter.
Marshall Wace sold 166,199 Medifast shares in Q2 2025, an estimated $2.24M.
Marshall Wace first reported a position in Medifast in Q2 2016 and held it in 12 quarters.
Marshall Wace's Medifast position peaked at $9.56M in Q2 2019.
120 funds tracked by Wall St. Rank held Medifast as of Q2 2025.

Based on Marshall Wace's 13F filing for Q2 2025, filed 13 Aug 2025.